Biovac

Company Overview

Snapshot

Founded in December 1989, Biovac operates with 11–50 employees. The company specializes in developing and producing vaccines and pharmaceuticals for animal health, a field it significantly advanced with the approval of a new Salmonella live vaccine in July 2010.

Business overview

Biovac develops and produces vaccines and pharmaceuticals aimed at preventing and treating animal diseases. The company's core technology includes the production of vitamin preparations, disinfectants, and pest-control products. It serves the animal health market, operating within the Health Tech & Life Sciences sector, specifically focusing on Pharma & Medical Biotechnology and Ag Tech.

Strategic signal

In July 2010, Biovac received approval for a new Salmonella live vaccine. This milestone indicates the company's capability in developing effective biological solutions for animal health, validating its research and development efforts and signaling its potential for further innovation in veterinary medicine.

Company Intelligence Q&A

What is Biovac's primary focus?

Biovac primarily focuses on the development and production of vaccines and pharmaceuticals to prevent and treat animal diseases, alongside producing vitamin preparations, disinfectants, and pest-control products.

When was Biovac founded?

Biovac was founded in December 1989.

What significant product approval did Biovac achieve?

In July 2010, Biovac achieved approval from the Israeli Ministry of Agriculture for a new Salmonella live vaccine, as reported by World Poultry.

What markets does Biovac serve?

Biovac serves the global market with its animal health products, including veterinary vaccines, disinfectants, and pesticides.

Does Biovac engage in research and development?

Yes, Biovac invests heavily in research and development, operating its own production laboratories, including a BSL3 laboratory and a Beta Lactam production alignment.